Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript

Unidentified Participant: Okay. I appreciate that. And then maybe last, just on the RIVER trial that it’s stratified, obviously, as you said, the primary endpoint with a reduction of cost. Should we be expecting that breakdown at the time of top line to better understand the efficacy in these sub-populations or I guess just some better color on what we should be expecting at the top line readout when that occurs? Thank you.

David Clark: Yeah. No. You are correct in that assumption. We would plan — we’re doing the overall population and also these two subpopulations — that would be — that’s what we will be analyzing and would plan to announce those results with the top line data readout.

Unidentified Participant: Awesome. Appreciate it and thank you for taking our questions. I’ll turn back in the queue.

Jennifer Good: Thank you, William.

Operator: I am not showing any further questions. This concludes our question-and-answer session. I would like to turn the conference back over to Jennifer Good for any closing remarks.

Jennifer Good: Thank you. We are expecting a milestone year with regards to our clinical trials data for Haduvio. We see an exciting road ahead for Trevi and look forward to focusing on execution of our clinical trials to get to data in these important indications beginning in the second half of this year. We would like to thank everybody for participating in today’s call and are available after the call for any follow-up questions you may have. Thank you.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.